BioCentury | Aug 25, 2003
Finance

Aging the rally

...things happen in stages, and tiers move independently," said Jonas Alsenas, manager of ING Barings Furman Selz's...
BioCentury | Aug 11, 2003
Finance

Ebb & Flow

...IPO window "all depends on the next manufacturing number," said Alsenas, manager for ING Barings Furman Selz's...
BioCentury | Nov 4, 2002
Emerging Company Profile

Corporate Profile

...International; SG Capital Partners; Bear Stearns Health; Innoventures; Connecticut Innovations; KBL Healthcare; GE Capital; ING Furman Selz...
BioCentury | Jul 8, 2002
Finance

Ebb & Flow

..."I thought the Alkermes news was just chilling," said Jonas Alsenas, manager for ING Barings Furman Selz's...
BioCentury | May 13, 2002
Strategy

Pharma's future

...invalidated patent's expiration date (see BioCentury, June 4, 2001). Jonas Alsenas, manager for ING Barings Furman Selz's...
BioCentury | Apr 1, 2002
Finance

1Q Financial Markets Review: Hoping for backloading

...biotech bubble that began on Sept. 30, 1999. Finally, Jonas Alsenas, manager of ING Barings Furman Selz's...
BioCentury | Jan 28, 2002
Financial News

Achillion raises $41 million

...Bear Stearns Health Innoventures; Atlas Venture; Schroder Ventures; Advent International; Connecticut Innovations; KBL Healthcare; ING Furman Selz...
BioCentury | Jan 28, 2002
Finance

Ebb & Flow

...B. Other investors were Atlas Venture; Schroder Ventures; Advent International; Connecticut Innovations; KBL Healthcare; ING Furman Selz...
BioCentury | Sep 24, 2001
Finance

Ebb & Flow

...director of trading. Hackett most recently served as senior managing director of equity trading at Furman Selz...
BioCentury | Sep 10, 2001
Finance

Ebb & Flow

...raise an additional $12 million in the financing round. Investors included Wanger Asset Management; ING Furman Selz...
Items per page:
1 - 10 of 43
BioCentury | Aug 25, 2003
Finance

Aging the rally

...things happen in stages, and tiers move independently," said Jonas Alsenas, manager of ING Barings Furman Selz's...
BioCentury | Aug 11, 2003
Finance

Ebb & Flow

...IPO window "all depends on the next manufacturing number," said Alsenas, manager for ING Barings Furman Selz's...
BioCentury | Nov 4, 2002
Emerging Company Profile

Corporate Profile

...International; SG Capital Partners; Bear Stearns Health; Innoventures; Connecticut Innovations; KBL Healthcare; GE Capital; ING Furman Selz...
BioCentury | Jul 8, 2002
Finance

Ebb & Flow

..."I thought the Alkermes news was just chilling," said Jonas Alsenas, manager for ING Barings Furman Selz's...
BioCentury | May 13, 2002
Strategy

Pharma's future

...invalidated patent's expiration date (see BioCentury, June 4, 2001). Jonas Alsenas, manager for ING Barings Furman Selz's...
BioCentury | Apr 1, 2002
Finance

1Q Financial Markets Review: Hoping for backloading

...biotech bubble that began on Sept. 30, 1999. Finally, Jonas Alsenas, manager of ING Barings Furman Selz's...
BioCentury | Jan 28, 2002
Financial News

Achillion raises $41 million

...Bear Stearns Health Innoventures; Atlas Venture; Schroder Ventures; Advent International; Connecticut Innovations; KBL Healthcare; ING Furman Selz...
BioCentury | Jan 28, 2002
Finance

Ebb & Flow

...B. Other investors were Atlas Venture; Schroder Ventures; Advent International; Connecticut Innovations; KBL Healthcare; ING Furman Selz...
BioCentury | Sep 24, 2001
Finance

Ebb & Flow

...director of trading. Hackett most recently served as senior managing director of equity trading at Furman Selz...
BioCentury | Sep 10, 2001
Finance

Ebb & Flow

...raise an additional $12 million in the financing round. Investors included Wanger Asset Management; ING Furman Selz...
Items per page:
1 - 10 of 43